5 Best Day Trading Stocks To Buy

1. Nkarta, Inc. (NASDAQ:NKTX)

Number of Hedge Fund Holders: 12 

Average Trading Volume as of November 2: 4.8 Million

Share Price Gain in Past Month: 45%  

Nkarta, Inc. (NASDAQ:NKTX) is a clinical-stage biopharmaceutical company that develops and commercializes cell therapies for cancer treatment. The firm focuses on cellular immunotherapy that involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Lead product candidates include NKX101 and NKX019. The shares have climbed in the past few weeks after the firm revealed that drug agencies had approved Phase 1 testing of NKX019 for lupus nephritis. The firm also said it was cutting costs to extend the cash runway into 2026.

On October 18, HC Wainwright analyst Emily Bodnar maintained a Buy rating on Nkarta, Inc. (NASDAQ:NKTX) stock and lowered the price target to $10 from $16, noting that a lot of uncertainty persists as the company optimizes doses and dosing regimens for new drugs. 

Among the hedge funds being tracked by Insider Monkey, Boston-based investment firm RA Capital Management is a leading shareholder in Nkarta, Inc. (NASDAQ:NKTX) with 7.8 million shares worth more than $17 million. 

At the end of the second quarter of 2023, 12 hedge funds in the database of Insider Monkey held stakes worth $30 million in Nkarta, Inc. (NASDAQ:NKTX), compared to 17 in the previous quarter worth $59 million.

You can also take a peek at 12 Countries That Produce The Best Cosmetics and Top 15 3D Companies in the World.